Evaluation of Pharmacokinetic and Toxicological Parameters of Arnica Tincture after Dermal Application In Vivo
ABSTRACT: Cutaneous leishmaniasis (CL) is classified as a neglected tropical disease by the World Health Organization. As the standard drugs for the treatment of this disease suffer from severeunwanted effects, new effective and safe therapeutic options are required. In our previous work, Arnica tin...
- Autores:
-
Robledo Restrepo, Sara María
Jürgens, Franziska M.
Schmidt, Thomas J.
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2022
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/44293
- Acceso en línea:
- https://hdl.handle.net/10495/44293
- Palabra clave:
- Arnica
Lactonas
Lactones
Leishmaniasis Cutánea
Leishmaniasis, Cutaneous
Helenalina
Helenalin
https://id.nlm.nih.gov/mesh/D018650
https://id.nlm.nih.gov/mesh/D007783
https://id.nlm.nih.gov/mesh/D016773
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by/2.5/co/
| id |
UDEA2_cfa097d315390d906828d6ef13d8b542 |
|---|---|
| oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/44293 |
| network_acronym_str |
UDEA2 |
| network_name_str |
Repositorio UdeA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Evaluation of Pharmacokinetic and Toxicological Parameters of Arnica Tincture after Dermal Application In Vivo |
| title |
Evaluation of Pharmacokinetic and Toxicological Parameters of Arnica Tincture after Dermal Application In Vivo |
| spellingShingle |
Evaluation of Pharmacokinetic and Toxicological Parameters of Arnica Tincture after Dermal Application In Vivo Arnica Lactonas Lactones Leishmaniasis Cutánea Leishmaniasis, Cutaneous Helenalina Helenalin https://id.nlm.nih.gov/mesh/D018650 https://id.nlm.nih.gov/mesh/D007783 https://id.nlm.nih.gov/mesh/D016773 |
| title_short |
Evaluation of Pharmacokinetic and Toxicological Parameters of Arnica Tincture after Dermal Application In Vivo |
| title_full |
Evaluation of Pharmacokinetic and Toxicological Parameters of Arnica Tincture after Dermal Application In Vivo |
| title_fullStr |
Evaluation of Pharmacokinetic and Toxicological Parameters of Arnica Tincture after Dermal Application In Vivo |
| title_full_unstemmed |
Evaluation of Pharmacokinetic and Toxicological Parameters of Arnica Tincture after Dermal Application In Vivo |
| title_sort |
Evaluation of Pharmacokinetic and Toxicological Parameters of Arnica Tincture after Dermal Application In Vivo |
| dc.creator.fl_str_mv |
Robledo Restrepo, Sara María Jürgens, Franziska M. Schmidt, Thomas J. |
| dc.contributor.author.none.fl_str_mv |
Robledo Restrepo, Sara María Jürgens, Franziska M. Schmidt, Thomas J. |
| dc.contributor.researchgroup.spa.fl_str_mv |
Programa de Estudio y Control de Enfermedades Tropicales (PECET) |
| dc.subject.decs.none.fl_str_mv |
Arnica Lactonas Lactones Leishmaniasis Cutánea Leishmaniasis, Cutaneous |
| topic |
Arnica Lactonas Lactones Leishmaniasis Cutánea Leishmaniasis, Cutaneous Helenalina Helenalin https://id.nlm.nih.gov/mesh/D018650 https://id.nlm.nih.gov/mesh/D007783 https://id.nlm.nih.gov/mesh/D016773 |
| dc.subject.proposal.spa.fl_str_mv |
Helenalina Helenalin |
| dc.subject.meshuri.none.fl_str_mv |
https://id.nlm.nih.gov/mesh/D018650 https://id.nlm.nih.gov/mesh/D007783 https://id.nlm.nih.gov/mesh/D016773 |
| description |
ABSTRACT: Cutaneous leishmaniasis (CL) is classified as a neglected tropical disease by the World Health Organization. As the standard drugs for the treatment of this disease suffer from severeunwanted effects, new effective and safe therapeutic options are required. In our previous work, Arnica tincture showed promising antileishmanial effects in vitro and in vivo. For the potential treatment of human CL patients with Arnica tincture, data on the pharmacokinetic properties of the bioactive, antileishmanial compounds (the sesquiterpene lactone (STL) helenalin and its derivatives) are needed. Therefore, we studied the in vivo absorption of the bioactive compounds after the dermal application of Arnica tincture in rats. Moreover, we analyzed the blood plasma, urine, and feces of the animals by ultra-high-performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS). Although the majority (84%) of the applied STLs (1.0 mg) were absorbed, the concentrations in the plasma, urine, and feces were below the limit of detection (0.3 ng/mL) in the samples for UHPLC-HRMS analysis. This result may be explained by extensive metabolism and slow permeation accompanied by the accumulation of STLs in the skin, as described in our previous work. Accordingly, the plasma concentration of STLs after the topical application of Arnica tincture was very far from a dose where toxicity could be expected. Additionally, tests for corrosive or irritant activity as well as acute and repeated-dose dermal toxicity did not show any positive results after the administration of the amounts of Arnica tincture that would be needed for the treatment of CL. Consequently, in the treatment of CL patients with Arnica tincture, no toxic effects are expected, other than the known sensitization potential of the STLs. |
| publishDate |
2022 |
| dc.date.issued.none.fl_str_mv |
2022 |
| dc.date.accessioned.none.fl_str_mv |
2025-01-21T20:05:33Z |
| dc.date.available.none.fl_str_mv |
2025-01-21T20:05:33Z |
| dc.type.spa.fl_str_mv |
Artículo de investigación |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ART |
| dc.type.coarversion.spa.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| status_str |
publishedVersion |
| dc.identifier.citation.spa.fl_str_mv |
Jürgens FM, Robledo SM, Schmidt TJ. Evaluation of Pharmacokinetic and Toxicological Parameters of Arnica Tincture after Dermal Application In Vivo. Pharmaceutics. 2022 Nov 4;14(11):2379. doi: 10.3390/pharmaceutics14112379. |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/10495/44293 |
| dc.identifier.doi.none.fl_str_mv |
10.3390/pharmaceutics14112379 |
| dc.identifier.eissn.none.fl_str_mv |
1999-4923 1 |
| identifier_str_mv |
Jürgens FM, Robledo SM, Schmidt TJ. Evaluation of Pharmacokinetic and Toxicological Parameters of Arnica Tincture after Dermal Application In Vivo. Pharmaceutics. 2022 Nov 4;14(11):2379. doi: 10.3390/pharmaceutics14112379. 10.3390/pharmaceutics14112379 1999-4923 1 |
| url |
https://hdl.handle.net/10495/44293 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
Pharmaceutics |
| dc.relation.citationendpage.spa.fl_str_mv |
13 |
| dc.relation.citationissue.spa.fl_str_mv |
11 |
| dc.relation.citationstartpage.spa.fl_str_mv |
1 |
| dc.relation.citationvolume.spa.fl_str_mv |
14 |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Pharmaceutics |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by/2.5/co/ |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by/2.5/co/ https://creativecommons.org/licenses/by/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
13 páginas |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
MDPI |
| dc.publisher.place.spa.fl_str_mv |
Basilea, Suiza |
| institution |
Universidad de Antioquia |
| bitstream.url.fl_str_mv |
https://bibliotecadigital.udea.edu.co/bitstreams/229d04b4-6233-45ef-b1e7-60c3ea728916/download https://bibliotecadigital.udea.edu.co/bitstreams/8d137547-8a06-4d5b-859c-e42cdc8b64d1/download https://bibliotecadigital.udea.edu.co/bitstreams/2510f488-ec0e-4adb-80b2-ee2db55a8986/download https://bibliotecadigital.udea.edu.co/bitstreams/3645924e-b2ff-437f-8398-0b1421325c35/download https://bibliotecadigital.udea.edu.co/bitstreams/62e1c1b6-f2fb-4ceb-9b80-340c065fde2e/download https://bibliotecadigital.udea.edu.co/bitstreams/cdf8bf76-abe6-4a70-9015-4901a46f6256/download |
| bitstream.checksum.fl_str_mv |
ea4783f8abdc88c858eba489364b2c69 303fa5b3b314b546d7229859e2d75fe1 1646d1f6b96dbbbc38035efc9239ac9c 8a4605be74aa9ea9d79846c1fba20a33 7c3b20886c1c54069a345d4d416e26d1 be8592b947c2c78d4978c49b875969db |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional de la Universidad de Antioquia |
| repository.mail.fl_str_mv |
aplicacionbibliotecadigitalbiblioteca@udea.edu.co |
| _version_ |
1851052336900734976 |
| spelling |
Robledo Restrepo, Sara MaríaJürgens, Franziska M.Schmidt, Thomas J.Programa de Estudio y Control de Enfermedades Tropicales (PECET)2025-01-21T20:05:33Z2025-01-21T20:05:33Z2022Jürgens FM, Robledo SM, Schmidt TJ. Evaluation of Pharmacokinetic and Toxicological Parameters of Arnica Tincture after Dermal Application In Vivo. Pharmaceutics. 2022 Nov 4;14(11):2379. doi: 10.3390/pharmaceutics14112379.https://hdl.handle.net/10495/4429310.3390/pharmaceutics141123791999-4923 1ABSTRACT: Cutaneous leishmaniasis (CL) is classified as a neglected tropical disease by the World Health Organization. As the standard drugs for the treatment of this disease suffer from severeunwanted effects, new effective and safe therapeutic options are required. In our previous work, Arnica tincture showed promising antileishmanial effects in vitro and in vivo. For the potential treatment of human CL patients with Arnica tincture, data on the pharmacokinetic properties of the bioactive, antileishmanial compounds (the sesquiterpene lactone (STL) helenalin and its derivatives) are needed. Therefore, we studied the in vivo absorption of the bioactive compounds after the dermal application of Arnica tincture in rats. Moreover, we analyzed the blood plasma, urine, and feces of the animals by ultra-high-performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS). Although the majority (84%) of the applied STLs (1.0 mg) were absorbed, the concentrations in the plasma, urine, and feces were below the limit of detection (0.3 ng/mL) in the samples for UHPLC-HRMS analysis. This result may be explained by extensive metabolism and slow permeation accompanied by the accumulation of STLs in the skin, as described in our previous work. Accordingly, the plasma concentration of STLs after the topical application of Arnica tincture was very far from a dose where toxicity could be expected. Additionally, tests for corrosive or irritant activity as well as acute and repeated-dose dermal toxicity did not show any positive results after the administration of the amounts of Arnica tincture that would be needed for the treatment of CL. Consequently, in the treatment of CL patients with Arnica tincture, no toxic effects are expected, other than the known sensitization potential of the STLs.COL001509913 páginasapplication/pdfengMDPIBasilea, Suizahttp://creativecommons.org/licenses/by/2.5/co/https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Evaluation of Pharmacokinetic and Toxicological Parameters of Arnica Tincture after Dermal Application In VivoArtículo de investigaciónhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArnicaLactonasLactonesLeishmaniasis CutáneaLeishmaniasis, CutaneousHelenalinaHelenalinhttps://id.nlm.nih.gov/mesh/D018650https://id.nlm.nih.gov/mesh/D007783https://id.nlm.nih.gov/mesh/D016773Pharmaceutics1311114PharmaceuticsPublicationORIGINALRobledoSara_2022_DermalHumanSTL.pdfRobledoSara_2022_DermalHumanSTL.pdfArtículo de investigaciónapplication/pdf1143334https://bibliotecadigital.udea.edu.co/bitstreams/229d04b4-6233-45ef-b1e7-60c3ea728916/downloadea4783f8abdc88c858eba489364b2c69MD51trueAnonymousREADRobledoSara_2022_Dermal_Human_Pharmacokinetic.epubRobledoSara_2022_Dermal_Human_Pharmacokinetic.epubArtículo de investigaciónapplication/epub+zip238604https://bibliotecadigital.udea.edu.co/bitstreams/8d137547-8a06-4d5b-859c-e42cdc8b64d1/download303fa5b3b314b546d7229859e2d75fe1MD54falseAnonymousREADCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8927https://bibliotecadigital.udea.edu.co/bitstreams/2510f488-ec0e-4adb-80b2-ee2db55a8986/download1646d1f6b96dbbbc38035efc9239ac9cMD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/3645924e-b2ff-437f-8398-0b1421325c35/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADTEXTRobledoSara_2022_DermalHumanSTL.pdf.txtRobledoSara_2022_DermalHumanSTL.pdf.txtExtracted texttext/plain59892https://bibliotecadigital.udea.edu.co/bitstreams/62e1c1b6-f2fb-4ceb-9b80-340c065fde2e/download7c3b20886c1c54069a345d4d416e26d1MD55falseAnonymousREADTHUMBNAILRobledoSara_2022_DermalHumanSTL.pdf.jpgRobledoSara_2022_DermalHumanSTL.pdf.jpgGenerated Thumbnailimage/jpeg16023https://bibliotecadigital.udea.edu.co/bitstreams/cdf8bf76-abe6-4a70-9015-4901a46f6256/downloadbe8592b947c2c78d4978c49b875969dbMD56falseAnonymousREAD10495/44293oai:bibliotecadigital.udea.edu.co:10495/442932025-03-26 20:47:38.159http://creativecommons.org/licenses/by/2.5/co/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.coTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo= |
